Business
Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nStoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the third quarter of 2019.\n\n\n“Our successful IPO has put us in a strong financial position to rapidly advance STK-001 toward the clinic, invest in research to help us identify the most promising new genetic targets for our TANGO platform and continue to hire the talented team we need to get the job done,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “In August we initiated BUTTERFLY, our observational study of children and adolescents living with Dravet syndrome, which is designed to provide information about the natural course of the disease – including a range of effects beyond just seizures – that impact patient health and quality of life. We remain on track with our clinical plans for STK-001, our investigational new medicine for the treatment of Dravet syndrome. We have completed the toxicology studies for our investigational new drug application and have made good progress on the protocol for our planned Phase 1/2 study.”\n\n\nThird Quarter 2019 Business Highlights:\n\n\n\nOn August 6, 2019, we announced that the U.S Food and Drug Administration (FDA) granted orphan drug designation to our lead product candidate, STK-001, an investigational new medicine for Dravet syndrome, a severe and progressive form of epilepsy.\n\n\nOn August 20, 2019, we announced first patient enrollment in BUTTERFLY, an observational study of children and adolescents ages 2 to 18 with Dravet syndrome. The two-year study is designed to evaluate non-seizure comorbidities associated with the disease, including cognitive development, behavior, movement, communication skills, seizure frequency and sleep pattern. Data from the study will help inform clinical development plans for STK-001.\n\n\nOn September 11, 2019, Stoke announced the company has been added to the Russell 2000® and 3000® indexes effective September 20, 2019. Stoke’s addition is based on FTSE Russell’s quarterly update.\n\n\n\nRecent Developments:\n\n\n\nIn October 2019, the company expanded to more than 50 employees and announced the appointments of two new members of the senior leadership team: Robin A....